Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
Key claim: A phase II trial is evaluating whether curcumin supplementation (C3 complex/Bioperine) can reduce inflammatory response and improve symptoms in patients with CCUS, low-risk MDS, and MPNs.
Abstract
This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and myeloproliferative neoplasms (MPN). Chronic inflammation drives disease development and contributes to symptoms experienced by patients with CCUS, LR-MDS, and MPN. Curcumin has been shown to have anti-inflammatory and anti-cancer properties and has been studied in various chronic illnesses and hematologic diseases.
Why this matters
Chronic inflammation is a core driver of MPN symptoms and clonal progression, making anti-inflammatory dietary interventions a plausible adjunct strategy. This is the first prospective trial testing curcumin specifically in MPN-spectrum clonal hematologic conditions, and a positive readout would move curcumin from mechanism-plausible to mpn-direct evidence — the rare case where a lifestyle/supplement intervention gets disease-specific trial data.